Skip to content

Study · Animal study (in vivo) · dog · 2019

7 results

Effects of elamipretide on skeletal muscle in dogs with experimentally induced heart failure.

Sabbah HN, Gupta RC, Singh-Gupta V, Zhang K

ESC heart failure28 Jan 2019Cited by 30 (Europe PMC)

PMID30688415 (opens in a new tab)PMCIDPMC6437430 (opens in a new tab)DOI10.1002/ehf2.12408 (opens in a new tab)PepBankPUB-30688415
Read at sourcePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In dogs with chronic heart failure, elamipretide restored a near-normal skeletal muscle fibre-type composition, with a higher proportion of type 1 fibres than vehicle.

    In plain wordsIn dogs with heart failure, elamipretide brought the muscle fibre mix back close to normal compared with vehicle.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseSkeletal muscle type 1 fibre proportion
    Study

    dogn = 14

    Dogs with microembolization-induced chronic heart failure
    Comparator
    Vehicle (HF-CON)
    Outcome group
    Body composition · Musculoskeletal
    Studied dose
    0.5 mg/kg · subcutaneous · 3 monthsAs given in this study (dog).

    Measurements

    Type 1 fibre proportion
    31%
    HF + ELAM
    Type 1 fibre proportion
    23%
    HF-CON

    Source sentences

    Summary
    Treatment with ELAM restored a near-normal fibre-type composition (31 ± 7%, P < 0.05 vs. HF-CON).
    2 context sentences
    Summary · context
    The proportion of skeletal muscle type 1 fibres was lower in HF-CON dogs compared with normal dogs (23 ± 4 vs. 32 ± 5%, P < 0.05).
    Summary · context
    Studies were performed in skeletal muscle biopsy specimens obtained from normal dogs (n = 7) and dogs with chronic intracoronary microembolization-induced HF (n = 14) treated with subcutaneous ELAM 0.5 mg/kg (HF + ELAM, n = 7) or vehicle (normal saline control, HF-CON, n = 7).
  2. 02LabEx vivo tissueMechanism

    In skeletal muscle mitochondria from dogs with heart failure, in vitro exposure to elamipretide increased adenosine diphosphate-dependent respiration.

    In plain wordsIn lab tests, elamipretide raised the energy-related oxygen use of muscle mitochondria taken from dogs with heart failure.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseADP-dependent mitochondrial respiration after in vitro exposure
    Study

    dogn: not reported in source

    Dogs with microembolization-induced chronic heart failure
    Outcome group
    Mitochondrial function · Musculoskeletal
    Studied dose
    0.10 µM · 1 hAs given in this study (dog).

    Measurements

    ADP-dependent mitochondrial respiration
    183 natom O/min/mg protein
    HF dog mitochondria, 0.10 µM ELAM

    Source sentences

    Summary
    adenosine diphosphate-dependent mitochondrial respiration increased to 183 ± 18 natom O/min/mg protein
    2 context sentences
    Summary · context
    In mitochondria from skeletal muscle of HF dogs exposed to 0.10 μM ELAM
    Summary · context
    Mitochondria isolated from myofibrils of the vastus lateralis skeletal muscle exposed in vitro to ELAM for 1 h were used to assess mitochondrial function.
  3. 03LabEx vivo tissueMechanism

    In skeletal muscle mitochondria from dogs with heart failure, in vitro exposure to elamipretide increased mitochondrial membrane potential.

    In plain wordsIn lab tests, elamipretide raised the membrane potential of muscle mitochondria taken from dogs with heart failure.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseMitochondrial membrane potential after in vitro exposure
    Study

    dogn: not reported in source

    Dogs with microembolization-induced chronic heart failure
    Outcome group
    Mitochondrial function · Musculoskeletal
    Studied dose
    0.10 µM · 1 hAs given in this study (dog).

    Measurements

    Mitochondrial membrane potential
    0.3 red/green fluorescence ratio
    HF dog mitochondria, 0.10 µM ELAM

    Source sentences

    Summary
    membrane potential increased to 0.30 ± 0.03 red/green fluorescence ratio
    2 context sentences
    Summary · context
    In mitochondria from skeletal muscle of HF dogs exposed to 0.10 μM ELAM
    Summary · context
    Mitochondria isolated from myofibrils of the vastus lateralis skeletal muscle exposed in vitro to ELAM for 1 h were used to assess mitochondrial function.
  4. 04LabEx vivo tissueMechanism

    In skeletal muscle mitochondria from dogs with heart failure, in vitro exposure to elamipretide increased the mitochondrial permeability transition pore measure.

    In plain wordsIn lab tests, elamipretide raised a mitochondrial pore measure in muscle mitochondria taken from dogs with heart failure.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseMitochondrial permeability transition pore after in vitro exposure
    Study

    dogn: not reported in source

    Dogs with microembolization-induced chronic heart failure
    Outcome group
    Mitochondrial function · Musculoskeletal
    Studied dose
    0.10 µM · 1 hAs given in this study (dog).

    Measurements

    Mitochondrial permeability transition pore
    54 RLU
    HF dog mitochondria, 0.10 µM ELAM

    Source sentences

    Summary
    mitochondrial permeability transition pore increased to 54 ± 4 RLU
    2 context sentences
    Summary · context
    In mitochondria from skeletal muscle of HF dogs exposed to 0.10 μM ELAM
    Summary · context
    Mitochondria isolated from myofibrils of the vastus lateralis skeletal muscle exposed in vitro to ELAM for 1 h were used to assess mitochondrial function.
  5. 05LabEx vivo tissueMechanism

    In skeletal muscle mitochondria from dogs with heart failure, in vitro exposure to elamipretide increased the maximum rate of adenosine triphosphate synthesis.

    In plain wordsIn lab tests, elamipretide raised the top rate of energy (ATP) production in muscle mitochondria taken from dogs with heart failure.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseMaximum rate of ATP synthesis after in vitro exposure
    Study

    dogn: not reported in source

    Dogs with microembolization-induced chronic heart failure
    Outcome group
    Mitochondrial function · Musculoskeletal
    Studied dose
    0.10 µM · 1 hAs given in this study (dog).

    Measurements

    Maximum rate of ATP synthesis
    4423 RLU/µg protein
    HF dog mitochondria, 0.10 µM ELAM

    Source sentences

    Summary
    maximum rate of adenosine triphosphate synthesis increased to 4423 ± 414
    2 context sentences
    Summary · context
    In mitochondria from skeletal muscle of HF dogs exposed to 0.10 μM ELAM
    Summary · context
    Mitochondria isolated from myofibrils of the vastus lateralis skeletal muscle exposed in vitro to ELAM for 1 h were used to assess mitochondrial function.
  6. 06LabEx vivo tissueMechanism

    In skeletal muscle mitochondria from dogs with heart failure, in vitro exposure to elamipretide increased cytochrome c oxidase activity.

    In plain wordsIn lab tests, elamipretide raised cytochrome c oxidase activity in muscle mitochondria taken from dogs with heart failure.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseCytochrome c oxidase activity after in vitro exposure
    Study

    dogn: not reported in source

    Dogs with microembolization-induced chronic heart failure
    Outcome group
    Mitochondrial function · Musculoskeletal
    Studied dose
    0.10 µM · 1 hAs given in this study (dog).

    Measurements

    Cytochrome c oxidase activity
    2033 natom O/min/mg protein
    HF dog mitochondria, 0.10 µM ELAM

    Source sentences

    Summary
    cytochrome c oxidase activity increased to 2033 ± 191 natom O/min/mg protein
    2 context sentences
    Summary · context
    In mitochondria from skeletal muscle of HF dogs exposed to 0.10 μM ELAM
    Summary · context
    Mitochondria isolated from myofibrils of the vastus lateralis skeletal muscle exposed in vitro to ELAM for 1 h were used to assess mitochondrial function.
  7. 07LabEx vivo tissueMechanism

    In skeletal muscle mitochondria from normal dogs, in vitro exposure to elamipretide had no effect on mitochondrial function parameters.

    In plain wordsIn lab tests, elamipretide did not change the function of muscle mitochondria taken from normal dogs.

    Peptide
    Elamipretide (SS-31)
    Outcome
    No significant changeMitochondrial function in normal dog mitochondria after in vitro exposure
    Study

    dogn: not reported in source

    Dogs with microembolization-induced chronic heart failure
    Outcome group
    Mitochondrial function · Musculoskeletal
    Studied dose
    Dose not stated · 1 hAs given in this study (dog).

    Source sentences

    Summary
    Exposure of skeletal muscle myofibrillar mitochondria from normal dogs to ELAM had no effect on mitochondrial function parameters.
    1 context sentence
    Summary · context
    Mitochondria isolated from myofibrils of the vastus lateralis skeletal muscle exposed in vitro to ELAM for 1 h were used to assess mitochondrial function.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.